Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853662 | 0.98 | ACHE (0.52) | ACHEHRH3HSD11B1CHRM5ADRA2C | |
| SCHEMBL23895398 | 0.98 | ACHE (0.52) | ACHEHRH3HSD11B1CHRM5ADRA2C | |
| SCHEMBL26047170 | 0.93 | ACHE (0.45) | ACHEHRH3HSD11B1CHRM5ADRA2C | |
| SCHEMBL22142238 | 0.91 | ACHE (0.48) | ACHEHRH3HSD11B1CARM1PRMT6 | |
| SCHEMBL12368089 | 0.91 | ACHE (0.48) | ACHEHRH3HSD11B1CARM1PRMT6 | |
| SCHEMBL22142662 | 0.91 | ACHE (0.48) | ACHEHRH3HSD11B1CARM1PRMT6 | |
| SCHEMBL81186 | 0.86 | — | — | |
| Fluoride SCHEMBL30331029 | 0.84 | ACHE (0.48) | ACHEHRH3CARM1PRMT6PRMT1 | |
| Ammonia Solution, Strong SCHEMBL1492464 | 0.84 | ACHE (0.48) | ACHEHRH3CARM1PRMT6PRMT1 | |
| SCHEMBL23182993 | 0.83 | KDM4E (0.49) | ACHEHRH3HSD11B1CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ACHE 3715/4885HRH3 3604/4885HSD11B1 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.